Home › Funds › Siren, L.L.C. › RYTM

Siren, L.L.C. position in RYTM

Rhythm Pharmaceuticals, Inc. · Health Care

Siren, L.L.C. reported holding 1,086,275 shares of RYTM (Rhythm Pharmaceuticals, Inc.) in its Q3 2026 13F filing — a position valued at US$103.4M, representing 2.46% of its reported portfolio and ranking #10 among its reported holdings. Siren, L.L.C. has disclosed RYTM holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

Latest position (Q3 2026)1.09M sh
Reported value held$103.43M
Portfolio Weight2.46%
First reportedQ1 2025
Last changeReduce
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Siren, L.L.C.'s RYTM position evolved

Siren, L.L.C. first disclosed a stake in RYTM in Q1 2025 at 277,533 shares (US$14.7M). The position peaked in Q2 2026 at 1,136,275 shares, worth US$126.2M. Across 7 filings, Siren, L.L.C. increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,086,275 shares valued at US$103.4M — a reduction of -50,000 shares quarter over quarter.. Notable position changes include a 48% increase in Q2 2025 (shares rose 60% over the following quarter), a 45% increase in Q1 2026 (shares rose 28% over the following quarter), a 57% increase in Q2 2026 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 277.53K $14.70M New
Q2 2025 409.74K $25.89M Add
Q3 2025 499.98K $50.49M Add
Q4 2025 499.98K $53.52M Hold
Q1 2026 725.51K $63.10M Add
Q2 2026 1.14M $126.16M Add
Q3 2026 1.09M $103.43M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (Rhythm Pharmaceuticals, Inc.) is a Health Care company. 50 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has Siren, L.L.C. held RYTM?

Siren, L.L.C. has disclosed RYTM holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is Siren, L.L.C.'s current position in RYTM?

As of Q3 2026, Siren, L.L.C. holds 1.09M shares of RYTM (Rhythm Pharmaceuticals, Inc.), valued at $103.43M, representing 2.46% of its reported portfolio and ranking #10.

Has Siren, L.L.C. been buying or selling RYTM?

In the latest 13F filing (Q3 2026), Siren, L.L.C. reduced its position in RYTM. The position peaked in Q2 2026 at 1.14M shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.